Idorsia IDIA

SWX: IDIA | ISIN: CH0363463438 18/09/2026

4,836 CHF (-1,31%)

(-1,31%) 18/09/2026

Grafiek Idorsia Ltd

Grafiek Idorsia Ltd

1 dag1d -1,31%
1 week1w -3,24%
1 maand1m -13,64%
3 maanden3m -16,19%
6 maanden6m 53,52%
1 jaar1j 24,16%
5 jaar5j -78,54%

Idorsia Ltd in het nieuws

Toon enkel gratis nieuws

11 augustus 2026 · Idorsia acknowledges the DEA proposal to reclassify dual orexin receptor antagonists to the lowest schedule – Schedule V · Persbericht

30 juli 2026 · QUVIVIQ sales increased 62% year-on-year as Idorsia advances key drivers of future growth · Persbericht

27 juli 2026 · Idorsia advances global rollout of QUVIVIQ with Jamjoom Pharma partnership in Saudi Arabia and the Levant · Persbericht

23 juli 2026 · Invitation to Idorsia's HY 2026 Financial Reporting webcast and conference call · Persbericht

1 juli 2026 · Idorsia appoints Roland Wandeler as Chief Executive Officer · Persbericht

26 juni 2026 · Idorsia confirms successful closing of Pharmakon loan agreement and full repayment of New Money Facility · Persbericht

9 juni 2026 · Idorsia strengthens financial position with up to CHF 250 million loan from Pharmakon · Persbericht

1 juni 2026 · Idorsia reports new positive results with its breakthrough C. difficile vaccine – underscoring the unique potential of its glycan technology · Persbericht

1 juni 2026 · New analysis of Idorsia’s aprocitentan demonstrates significant and sustained reduction in albuminuria in patients with uncontrolled / resistant hypertension · Persbericht

6 mei 2026 · Shareholders vote in favor of all proposals by the Board at Idorsia’s Annual General Meeting 2026 · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe